sapanisertib + paclitaxel + trastuzumab

Sapanisertib + paclitaxel + trastuzumab is an investigational combination regimen composed of three drugs with complementary mechanisms of action: sapanisertib, a selective dual inhibitor of mTORC1 and mTORC2; paclitaxel, a microtubule-stabilizing chemotherapeutic agent; and trastuzumab, a recombinant humanized monoclonal antibody targeting the HER2/ERBB2 receptor. This combination is being studied primarily in advanced or recurrent solid tumors, including endometrial and breast cancer, to assess potential synergistic antitumor effects especially in HER2-positive disease. Sapanisertib (TAK-228, MLN0128) is developed by Takeda and blocks signaling through mTORC1/2 to inhibit tumor cell growth and survival. Paclitaxel disrupts mitotic spindle function, causing apoptosis in dividing cells. Trastuzumab inhibits HER2-mediated signaling and promotes antibody-dependent cellular cytotoxicity in HER2-overexpressing cells[1][3].